Category: 3. Business

  • Cursor internal AI Help Desk handles 80% of employees’ support tickets

    Cursor internal AI Help Desk handles 80% of employees’ support tickets

    AI coding-assistant start-up Cursor isn’t just using artificial intelligence to help developers write code, it’s deploying AI across its own internal operations, CEO, Michael Truell, told the audience at Fortune’s Brainstorm AI in San Francisco.

    Truell said the company had already automated roughly 80% of its customer support tickets with the help of the technology. He said the company had also implemented an internal AI-powered communication system that allows employees to query information across the organization. “We’ve actually done a lot of work internally on customizing that setup,” he said.

    Cursor also uses AI for internal communications, he said. “We have a system where folks can ask any question about the company and get it answered by an AI,” Truell said, as well as an project with “a few forward deployed engineers internally embedded throughout, building custom tooling right now for operations, for sales and experimenting,” he said. 

    Across the enterprise software landscape, some larger organizations are increasingly coming up against adoption challenges when attempting to integrate AI into workflows. 

    Data silos—where information is trapped in disconnected systems—prevent AI tools from accessing the full context they need to be useful, and technical sprawl—the accumulation of disparate tools and platforms over years of growth— can create integration issues. Many organizations are finding they need more dedicated technical expertise to help tailor AI models to specific business needs.

    Engineers are seeing productivity gains

    Cursor, which is valued at $29.3 billion, said last month it had crossed $1 billion in annualized revenue and now has more than 300 employees. The company has seen rapid growth since it was founded by a team of four MIT graduates in 2022. The company’s AI coding tool, which first launched in 2023, has been popular with software who use it to help both generate and edit code. 

    There has been some conflicting research about how helpful AI tools actually are for software engineering. A July 2025 study by the nonprofit research group METR found that experienced developers working on large, mature codebases actually took 19% longer to complete tasks when using AI tools such as Cursor and Claude, despite believing they had worked 20% faster. The researchers attributed the slowdown to time spent prompting AI, waiting for responses, and time reviewing generated code.

    A recent study conducted by University of Chicago found that teams using Cursor’s AI coding assistant in large companies merged 39% more pull requests (PRs) compared to non-users. The research also showed that senior developers created more detailed plans before writing code and demonstrated greater skill working with AI agents.

    “A lot of folks think that junior developers get the most out of AI,” Truell said. But “when these academics went in and looked at the data, it looked like senior engineers actually were more effective in using the tools and were accepting code at higher rates and were getting more value from that.”

    Truell noted that this surprised him as well: “We want to dig into to understand exactly why that’s the case.”

    Continue Reading

  • Has Uranium Energy’s 79% 2025 Surge Already Priced In Its Nuclear Fuel Growth Story?

    Has Uranium Energy’s 79% 2025 Surge Already Priced In Its Nuclear Fuel Growth Story?

    • Wondering if Uranium Energy is still a smart buy after its massive run, or if the easy money has already been made? This breakdown will help you decide if the current price still makes sense.

    • The stock has surged 16.1% over the last week, 11.9% over the past month, and is now up 79.1% year to date, building on a huge 70.4% gain over the last year and an eye catching 753.1% rise over five years.

    • These moves have come as uranium prices stay elevated and geopolitical tensions keep nuclear fuel security in the spotlight, drawing more institutional attention to producers and developers. Uranium Energy has also been active in expanding its resource base and advancing U.S. focused projects, which has helped fuel a narrative of long term strategic importance rather than just a short term commodity trade.

    • Despite all that excitement, Uranium Energy only scores 1 out of 6 on our valuation checks. In this article we will unpack what traditional valuation methods say, where they may fall short for a cyclical, growth driven uranium play, and introduce a more nuanced way to think about what this stock might be worth by the end of the article.

    Uranium Energy scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    The Discounted Cash Flow model estimates what a company is worth by projecting its future cash flows and discounting them back to today in $ terms. For Uranium Energy, this 2 stage Free Cash Flow to Equity model starts from a last twelve month free cash outflow of about $67.3 Million, then uses analyst forecasts for the next few years before extrapolating further out.

    Analysts see free cash flow turning positive and ramping up to around $86.7 Million by 2028. Beyond that, Simply Wall St extends those projections, with free cash flow rising to roughly $378.0 Million by 2035 as projects mature and scale. All of those future cash flows are discounted back to today to arrive at an estimated intrinsic value of $13.57 per share.

    With the DCF suggesting Uranium Energy is about 0.6% above its fair value, the model implies the stock is basically trading in line with its projected cash generating potential rather than at a clear bargain or obvious bubble level.

    Result: ABOUT RIGHT

    Uranium Energy is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment’s notice. Track the value in your watchlist or portfolio and be alerted on when to act.

    UEC Discounted Cash Flow as at Dec 2025

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Uranium Energy.

    Continue Reading

  • First Brands rescue loan tumbles in value as bankruptcy drags on

    First Brands rescue loan tumbles in value as bankruptcy drags on

    Unlock the Editor’s Digest for free

    The $1.1bn loan First Brands secured to stabilise its business at the start of its bankruptcy dropped in value on Monday, in a sign that the company’s attempt to quickly reorganise its finances is foundering.

    The so-called debtor-in-possession loan, provided by a cadre of existing First Brands senior lenders in September, was quoted by trading desks between 69 and 72 cents on the dollar, down 20 cents from Friday, according to people familiar with the matter.

    Its rapid collapse signals that lenders are looking to pare back their exposure to the auto parts maker or get out entirely, as conflict over who has rights to what remaining collateral drags out an expensive bankruptcy process.

    “Once you start untangling the Gordian knot, it gets murkier and murkier,” said one person familiar with the trading. “You’re getting more clarity on how little clarity you have as time goes on.”

    Court filings showed Marathon Asset Management, Beach Point Capital Management and Redwood Capital Management were among the largest holders of the loan. But trading has intensified in recent weeks and some have cut or changed their initial positions.

    A spokesperson for Marathon said the firm had sold its entire exposure to the loan at prices above 105 cents on the dollar.

    Another investor said “people were panicking” and were dumping their positions, worried that the company would either need to secure a new senior loan or face further financial stress. If First Brands did strike a new loan, it could be entitled to repayment before the current rescue loan — further eroding the existing loan’s value.

    First Brands and Beach Point declined to comment. Redwood did not immediately respond to a request for comment.

    Debtor-in-possession loans, which have the highest claim on a bankrupt company’s assets, rarely trade below 100 cents on the dollar. Having traded well above 100 cents, the First Brands loan began to fall sharply late last week.

    The group of First Brands lenders that made the September loan was expected to bid for the company’s assets using the value of the $1.1bn rescue loans as well as more than $3bn in loans they made to the company before it went bankrupt.

    More than 80 asset managers and hedge funds own parts of the bankruptcy loan, which was hastily put together in the days leading up to First Brands’ bankruptcy in late September, according to court filings.

    A committee of First Brands’ creditors, which is challenging the rescue loan terms, previously told the bankruptcy court that the loan would ultimately come with an annualised rate of return exceeding 70 per cent.

    Last month, Scott Greenberg, a lawyer for the lenders, told the court his clients expected to be fairly compensated for contributing “into a black box without a bottom”.

    Greenberg in October said his clients’ due diligence was roughly 10 to 20 per cent of what they would typically have done for a loan of “this size and complexity”.

    The bankruptcy thus far has been marred by conflicts over claims on collateral between various stakeholders in the company’s roughly $12bn debt stack. The company’s advisers have told the court that several billion dollars of cash has gone missing.

    The company’s new management has sued First Brands founder Patrick James for fraud, alleging he misappropriated hundreds of millions of dollars from the company for personal use and engaged in “fraudulent conduct”.

    Customers are now freezing payments to First Brands until the court clarifies who they owe money to.

    According to multiple people involved in the case, the fear is that the dwindling remaining value of the business, along with the missing cash, raises the risk that unsecured creditors and off-balance-sheet lenders will not be able to recover billions of dollars that they are owed.

    Continue Reading

  • Pre-Budget shopper ‘jitters’ dampen Black Friday sales

    Pre-Budget shopper ‘jitters’ dampen Black Friday sales

    Pre-Budget “jitters” among shoppers dampened a much-needed Black Friday boost for retailers, figures show.

    Total retail sales across the UK increased by 1.4% year on year in November – the weakest growth in six months despite elevated inflation, according to the British Retail Consortium (BRC) and KPMG.

    Food sales were up 3%, but even this was below the 12-month average growth of 3.6%.

    (BRC)

    Sales of products other than food increased by just 0.1% year on year, again below the 12-month average of 1.6%.

    Online non-food sales increased by 0.5% against a decline of 10.3% last November, and below the average across the year of 2.5%.

    Homeware and upholstery sold well as households prepared to host over the festive season, while fashion sales lagged as the mild first half of November dampened demand for winterwear.

    BRC chief executive Helen Dickinson said: “Pre-Budget jitters among shoppers meant the month of Black Friday did not deliver as strongly as retailers had hoped or the economy needed.

    “It has been a difficult year as retailers grappled with ever-rising cost pressures.

    “Looking ahead to 2026, it is time public policy started prioritising measures to revive consumer confidence and keep costs of doing business down so retailers can focus on growth strategies to maximise their contribution to economic recovery.”

    Linda Ellett, UK head of consumer, retail and leisure markets at KPMG, said: “November delivered some growth in retail sales, but many retailers will be disappointed that Black Friday period promotions failed to deliver the bigger boost that they were hoping for.

    “While the likes of computing and household appliances outperformed Black Friday week last year, total non-food sales growth across all categories was minimal overall.

    “Rising household costs and nervousness about the economy continue to impact discretionary buying.

    “But retailers will be hoping that Budget clarity has now provided more certainty for consumers about their ability to spend in the months ahead.”

    Separate figures from Barclays show consumer card spending fell 1.1% year-on-year in November – the greatest fall recorded since February 2021.

    The bank said overall retail spending dipped 1.1%, but retailers still enjoyed their busiest day of the year so far on Black Friday, with transaction volumes up 62.5% in comparison to the average day in 2025.

    Travel agents also enjoyed a Black Friday boost, up 10.7%, while streaming and subscriptions increased 3.5% thanks to hit shows such as Stranger Things and Pluribus.

    However pub spending slowed by 1.5%, with 42% of those aged 18 to 34 opting for alcohol-free drinks and 40% for alcohol-free activities.

    Consumer and economic confidence remained at 22% in November, on a par with October, while UK adults’ confidence in their household finances improved marginally from 63% to 64% – although this remains below 2025’s 70% average.

    Jack Meaning, chief UK economist at Barclays, said: “Even with a boost from Black Friday, consumer spending remained muted as we moved through the final quarter of the year.

    “2025 has been defined by this economic deceleration.

    “The question remains as to whether easing interest rates and falling inflation can offset this trend and spur a rebound in consumer spending, or whether tightening fiscal policy and continued uncertainty will see the malaise continue in 2026.”

    Continue Reading

  • Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis

    SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that that PECONDLE® (picankibart injection, R&D code: IBI112), its self-developed recombinant anti-interleukin-23p19 subunit monoclonal antibody, achieved both primary and key secondary efficacy endpoints in the Phase 3 CLEAR-2 study – a randomized withdrawal and retreatment clinical trial in Chinese participants with moderate-to-severe plaque psoriasis. As the first China-developed IL-23p19 monoclonal antibody, PECONDLE® received market approval from the National Medical Products Administration (NMPA) in November 2025 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

    This study (NCT06049810) is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial using a randomized withdrawal and retreatment design. It aims to evaluate the efficacy of subcutaneous picankibart in participants with moderate-to-severe plaque psoriasis during maintenance treatment and after withdrawal, following achievement of treatment targets. A total of 566 participants were enrolled and all received picankibart treatment through Week 32. Those who achieved ≥90% improvement in Psoriasis Area Severity Index (PASI 90) at Week 32 were re-randomized either to a maintenance group receiving picankibart 100 mg or 200 mg, or to a withdrawal group receiving placebo. The primary endpoint was the proportion of participants who maintained a PASI 90 response at Week 56. This endpoint objectively quantifies sustained high-level lesion clearance during long-term therapy, establishing a validated measure for efficacy durability and maintenance regimen superiority.

    The primary endpoint was met, demonstrating that quarterly dosing of picankibart sustained long-term efficacy superiority

    At Week 56, the proportions of participants maintaining PASI 90 response were 89.3% in the 100 mg group and 90.1% in the 200 mg group for picankibart maintenance treatment, both significantly higher than the corresponding withdrawal groups (37.7% and 51.7%, respectively; P < 0.0001 for both). These robust data demonstrate that quarterly dosing of picankibart provides sustained and reliable superior efficacy compared to treatment withdrawal.

    All key secondary endpoints were met, with picankibart delivering comprehensive improvements in both skin clearance and quality of life

    All secondary efficacy endpoints were successfully met, with significantly higher proportions of participants in the 100 mg and 200 mg picankibart maintenance groups versus the corresponding withdrawal groups achieving PASI 75, PASI 100 (complete skin clearance), sPGA score of 0 or 1, sPGA score of 0 (clear skin), and DLQI score 0/1 (dermatology life quality index) at Week 56 (P < 0.0001 for all comparisons). These results demonstrate that quarterly dosing of picankibart provides comprehensive and durable clinical benefits.

    Picankibart demonstrates durable efficacy post-withdrawal and significantly reduces relapse risk with maintenance treatment

    At Week 56, PASI 90 response was maintained in both 100 mg and 200 mg maintenance groups, whereas the corresponding withdrawal groups exhibited median efficacy durability of 20.4 weeks and 24.6 weeks (32.4 weeks and 36.6 weeks post-last dose of picankibart), respectively. Maintenance treatment with picankibart 100 mg and 200 mg significantly reduced the risk of losing PASI 90 response compared with the corresponding withdrawal groups (P < 0.0001). As indicated by the primary endpoint, nearly half of the participants in withdrawal groups still maintained skin clearance (PASI 90) even after 24 weeks of treatment discontinuation, confirming picankibart’s disease-modifying effect in achieving deep skin clearance for moderate-to-severe psoriasis.

    Picankibart demonstrated a favorable safety profile with no new safety signals identified

    Throughout the study, picankibart maintained a consistent safety profile, with no new safety signals observed compared to previous clinical trials.

    Professor Shi Yuling, the Principal Investigator of the Clinical Study, Shanghai Skin Disease Hospital, stated, “Existing evidence confirms that IL-23p19 antibodies offer sustained long-term efficacy and superior treatment convenience in psoriasis management. The CLEAR-2 study—China’s first randomized withdrawal and retreatment trial of a domestically developed IL-23p19 inhibitor (picankibart)—provides critical insight into the necessity of maintenance therapy, the durability of post-withdrawal, and effective retreatment strategies. We’re are greatly encouraged by its success in achieving both primary and secondary endpoints, which underscores picankibart’s exceptional long-term stability during maintenance therapy and its outstanding sustained response following treatment discontinuation. These results offer crucial assurance for chronic patients with chronic disease while empowering clinicians with evidence-based guidance to optimize long-term management.”

    Dr. Lei Qian, the Chief R&D Officer of General Biomedicine from Innovent Biologics, stated, “PECONDLE®’s successful Phase 3 CLEAR-2 results validate its core advantages as a next-generation IL-23p19 inhibitor: achieving deep, durable remission through quarterly dosing, coupled with favorable safety and significant quality-of-life improvements. As China’s first self-developed IL-23p19 biologic, these breakthrough findings enable us to deliver convenient, patient-friendly treatment options with verified efficacy for moderate-to-severe cases. We’ll continue exploring indication expansion through comprehensive lifecycle management, maximizing clinical value while addressing unmet needs such as treatment resistance.”

    About Psoriasis

    Psoriasis is a chronic, recurrent, inflammatory and systemic disease induced by genetic and environmental factors, affecting individuals of all ages and genders. It typically presents as scaly erythema or plaques, with non-infections, localized or widespread distribution. As a life-long noninfectious condition, psoriasis is notoriously difficult to treat. The disease can be categorized into psoriasis vulgaris (including guttate psoriasis and plaque psoriasis), pustular psoriasis, erythrodermic psoriasis and arthropathic psoriasis. Approximately 80%~90% of patients have plaque psoriasis, with nearly 30% of the cases being moderate-to-severe. Global psoriasis prevalence varies significantly, with over 7 million patients in China alone. Current systemic treatments in China include methotrexate (MTX), cyclosporine A, retinoic acids, small molecule target agents and biological agents. Since 2019, biologics have become a central focus in psoriasis treatment, with IL-23 inhibitors standing out due to their rapid onset, robust efficacy, good safety, and long-lasting effects, which are more advantageous in comprehensive and deep lesion clearance and prolonging relapse-free periods. 

    About PECONDLE® (Picankibart Injection)

    PECONDLE® (picankibart injection) is a monoclonal antibody independently developed by Innovent with proprietary intellectual property rights. This product specifically targets the IL-23p19 subunit, preventing IL-23 from binding to cell surface receptors. Picankibart has the potential to offer a more effective treatment option for patients with psoriasis, ulcerative colitis or other autoimmune diseases.

    PECONDLE® (picankibart injection) is approved by the NMPA of China for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy.

    Currently, multiple clinical studies of picankibart are underway, including:

    • Phase 3 study conducted in patients with moderate-to-severe plaque psoriasis (CLEAR-1);
    • Phase 3 study conducted in patients with moderate-to-severe plaque psoriasis with randomized withdrawal;
    • Phase 3 study in patients with moderate-to-severe plaque psoriasis who were previously treated with biologics;
    • Phase 2 study in patients with moderate-to-severe active ulcerative colitis;

    Except for the ongoing CLEAR-3 study, all other studies have met their primary endpoints.

    In addition, new clinical studies of picankibart in the treatment of adolescent psoriasis and adult psoriatic arthritis are initiated.

    About Innovent

    Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Takeda, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

    Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

    Statement:Innovent does not recommend the use of any unapproved drug (s)/indication (s).

    Forward-Looking Statement

    This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

    These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

    Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

    SOURCE Innovent Biologics

    Continue Reading

  • Trump gives Nvidia the OK to sell advanced AI chips to China

    Trump gives Nvidia the OK to sell advanced AI chips to China

    US President Donald Trump has announced that he will allow AI chip giant Nvidia to sell its advanced H200 chips to “approved customers” in China.

    “We will protect National Security, create American Jobs, and keep America’s lead in AI,” Trump said on social media on Monday.

    The decision will apply to other US chip companies like AMD and comes after extensive lobbying by Nvidia boss Jensen Huang, who visited Washington last week to drum up support.

    Nvidia – both the world’s leading chip firm and most valuable company – has found itself at the centre of a geopolitical tug-of-war between the US and China in recent months, and had been banned from selling its most advanced chips to Beijing.

    Trump reversed the chip-selling ban in July, but demanded that Nvidia pay 15% of its Chinese revenues to the US government.

    Beijing then reportedly ordered its tech companies to stop buying Nvidia chips manufactured for use in the Chinese market.

    “We applaud President Trump’s decision to allow America’s chip industry to compete to support high paying jobs and manufacturing in America,” Nvidia said in a statement provided to BBC News.

    Mr Huang told the BBC in September that the US needed “to make sure that people can access this technology from all over the world, including China.”

    He has also repeatedly warned that China, which has cultivated a chip production ecosystem of its own, was close behind the US in chip development.

    Nvidia hailed Trump’s announcement on Monday.

    “Offering H200 to approved commercial customers, vetted by the Department of Commerce, strikes a thoughtful balance that is great for America,” Nvidia said in its statement.

    The companies shares rose slightly on the news.

    Trump said “$25% [sic] will be paid to the United States of America” in his post.

    The BBC has reached out to the White House for clarification on the arrangement, which will likely face opposition from national security hawks in Congress.

    Researchers at Georgetown University’s Center for Security and Emerging Technology (CSET) said China’s People’s Liberation Army is using advanced chips designed by US companies to develop AI-enabled military capabilities.

    “By making it easier for the Chinese to access these high-quality AI chips, you enable China to more easily use and deploy AI system for military applications,” said Cole McFaul, senior research analyst at CSET. “They want to harness advanced chips for battlefield advantage.”

    Continue Reading

  • “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List – Biogen

    1. “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List  Biogen
    2. Real-World Data Support for Lecanemab in Early AD  Medscape
    3. Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at CTAD 2025  marketscreener.com
    4. Breakthrough Alzheimer’s drug ‘could slow disease by 8 years’  Qazinform
    5. Key facts: Biogen’s Alzheimer’s drug delays progression by 30%; CEO boosts shares  TradingView

    Continue Reading

  • Glean hits $200 million ARR, up from $100 million nine months back

    Glean hits $200 million ARR, up from $100 million nine months back

    Glean, last valued at $7.2 billion, has hit $200 million in annual recurring revenue, CEO Arvind Jain revealed at Fortune Brainstorm AI San Francisco. 

    “What’s driving all of this is the awareness from CEOs and executives that this is the time to invest in AI,” Jain said in an exclusive interview before the conference. “Everybody has been looking for a safe, secure, more appropriate version of ChatGPT for their employees. And we bring the capabilities that ChatGPT brings to consumers to business users, and in the context of their company.”

    Jain founded Glean in 2019, and the company has made its name in enterprise search and AI applications. In June, Glean raised its $150 million Series F, sending its valuation over $7 billion, a leap from the $4.6 billion valuation the company fetched in 2024. 

    “The biggest challenge that customers face with AI is the fact that AI technologies are actually not built for their companies,” said Jain. “Most of the AI technologies are built…on the data on the Internet, public data. And so when you bring those models…inside your company, and you try to actually make them do some work internally, they don’t really have any understanding of how your business works and your context.”

    And in an AI landscape with lots of ARR numbers floating around, Jain is clear: This ARR number includes only subscription revenues from their software—no consulting or services revenue. Jain adds that Glean’s contracts range from one to three years, and that there’s “no sub-one-year contract in our model.”

    Glean’s rise through the AI boom has been uniquely tied to the challenges that enterprises face when trying to apply AI. The much quoted MIT study from this summer—that 90% of generative AI pilots are failing—reflects the existential question for companies: Where does AI ROI actually come from?

    “There are two narratives,” said Jain. “One narrative of AI is that nothing works, and then the other one is that it’s taking off. It’s getting more serious. Companies are able to actually do many, many, many useful things with AI. And we’re definitely generating success and excitement for customers.”

    Continue Reading

  • PepsiCo reaches deal with activist Elliott to stave off proxy fight – Financial Times

    PepsiCo reaches deal with activist Elliott to stave off proxy fight – Financial Times

    1. PepsiCo reaches deal with activist Elliott to stave off proxy fight  Financial Times
    2. Exclusive | PepsiCo to Cut Costs, Lower Food Prices in Deal With Activist  The Wall Street Journal
    3. Pepsi settles with Elliott, will trim 20% of SKUs  Axios
    4. PepsiCo staffers nationwide — including Chicago — brace for layoff news  Crain’s Chicago Business
    5. PepsiCo Announces Priorities to Enhance Shareholder Value and Provides Preliminary 2026 Financial Outlook  Morningstar

    Continue Reading

  • Tagraxofusp/Azacitidine/Venetoclax Triplet Is Safe, Feasible in First-Line and R/R BPDCN

    Tagraxofusp/Azacitidine/Venetoclax Triplet Is Safe, Feasible in First-Line and R/R BPDCN

    The addition of azacitidine (Vidaza) and ventoclax (Venclexta) to tagraxofusp (Elzonris) was feasible in patients with first-line or relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN), and may increase both complete response (CR) rates and the number of patients proceeding the transplant compared with tagraxofusp alone, according to results from a phase 2 trial (NCT03113643) presented during the 2025 ASH Annual Meeting.1

    In previously untreated patients (n = 16), at a median follow-up of 16.7 months (95% CI, 8.6-26.6), the composite CR rate was 88%, comprising best responses of CR (50%), CR with incomplete hematologic recovery (CRi; 38%) and clinical CR (0%). The overall response rate (ORR) was 94%, including 1 partial response (PR; 6%). The median duration of response (DOR) was not reached (NR). No patients achieved stable disease (SD) or experienced disease progression (PD), and 1 patient was not evaluable due to early death.

    For patients with relapsed/refractory disease (n = 11), the composite CR rate was 64%; this included CR, CRi and CRc rates of 9%, 36% and 18%, respectively. The ORR was comprised entirely of CRs. SD was achieved by 27% of patients and 9% experienced PD. The median DOR was 7.2 months (95% CI, 5.5-36.4%). Of note, all but one patient in this cohort had disease relapse or death; the remaining patient had a median follow-up of 42.4 months.

    Notably, 63% and 55% of patients in the first-line and relapsed/refractory groups, respectively, proceeded directly to allogeneic stem cell transplant (SCT), including 10 of the 11 patients age 75 or older in the first-line cohort.

    Regarding safety, investigators reported that the toxicity profile of the tagraxofusp, azacitidine, and venetoclax triplet was as expected and consistent with prior studies of this regimen in patients with acute myeloid leukemia (AML).

    Moreover, the rate of capillary leak syndrome (CLS) was equivalent or lower with the triplet than with single-agent tagraxofusp, according to historical data. Overall, the CLS rate with the triplet was 14.8%; respective rates of grade 2 and 3 CLS were 11.1% and 3.7%, and no grade 4 or 5 CLS events occurred. All CLS events occurred in cycle 1 and were manageable with albumin and diuresis.

    “There is a high rate of known prior and concomitant hematologic malignancies in these patients with BPDCN,” lead study author Andrew A. Lane, MD, PhD, stated in an oral presentation of the data. “The addition of agents like azacitidine and venetoclax [to tagraxofusp] is attractive because it can have activity in those diseases that may not be as high with tagraxofusp alone. [Therefore,] we think [that this triplet] is an effective new treatment option for patients with BPDCN.”

    Lane serves as a physician and director of the Blastic Plasmacytoid Dendritic Cell Neoplasm Center at Dana-Farber Cancer Center, and is an associate professor of medicine at Harvard Medical School, both in Boston, Massachusetts.

    Key Takeaways From a Phase 2 Study of Tagraxofusp/Azacitidine/Venetoclax

    • This triplet regimen was found to be feasible in both previously untreated and relapsed/refractory BPDCN.
    • The regimen’s safety profile was as-expected and was deemed comparable to that of the triplet regimen in prior evaluations in AML.
    • Composite CR rates with the triplet in previously untreated and relapsed/refractory patient populations were 88% and 64%, respectively.

    What was the rationale for evaluating this triplet regimen both upfront and in the relapsed/refractory setting?

    “We previously found in the laboratory that tagraxofusp resistance in AML and BPCDN is mediated by DNA methylation and silencing of diphthamide genes, which are necessary for the cytotoxicity of diphtheria toxin, and that tagraxofusp resistance can be reversed with azacitidine treatment,” Lane explained. “We’ve also shown that BPDCN is highly dependent on BCL2 and sensitive to venetoclax.”

    Lane also noted clinical data from a phase 1b study (NCT03113643), which evaluated the safety of tagraxofusp plus azacitidine with or without venetoclax in AML. Results showed that 69% of patients with first-line AML who received the triplet (n = 26) achieved a best response of CR, 19% achieved a CRi, and 12% achieved a morphologic leukemia-free state. The median time to best response among these 18 patients was 55 days. Furthermore, there was no indication of increased toxicity with tagraxofusp with azacitidine with or without venetoclax in combination, and adverse effects (AEs) related to tagraxofusp were also as expected.

    How was this phase 2 trial designed?

    This phase 2 study enrolled patients 18 years of age or older with previously untreated or relapsed/refractory BPDCN onto separate cohorts. Patients were required to have albumin levels of 3.2 g/L or greater, alanine aminotransferse (ALT)/aspartate aminotransferase (AST) levels below 2.5 x the upper limit of normal (ULN), bilirubin levels below 1.5 x ULN, and creatinine levels below 1.5 x ULN; an ECOG performance status of 2 or lower; and normal cardiac ejection fractions. Screening lumbar puncture was required. Patients with asymptomatic central nervous system disease were permitted to enroll and receive intrathecal (IT) chemotherapy, and IT prophylaxis was both permitted and encouraged for all.

    Eligible patients received 12 µg/kg of tagraxofusp on days 4 through 6, 75 mg/m2 of azacitidine on days 1 through 7, and 400 mg of venetoclax on days 1 through 21 for a 28-day cycle. Venetoclax ramp-up occurred on days 1 through 3 of cycle 1. Notably, patients were hospitalized in cycle 1 until the completion of tagraxofusp administration to monitor for CLS. Outpatient treatment was allowed starting at cycle 2 and beyond.

    The study’s primary end point was safety, and key secondary end points included response rate, estimated progression-free survival (PFS) and overall survival (OS). Response evaluation in marrow, skin, and the extramedullary space was also conducted.

    What were the baseline characteristics of patients in this study?

    In the overall patient population (n = 27), the median age was 70 years (range, 21-81). Most patients were male (93%), White (93%), had non-Hispanic ethnicity (78%), and an ECOG performance status of 1 (63%). “Skin only” disease occurred in 30% of patients. Overall, 37% of patients had a prior or concomitant hematologic malignancy, including chronic myelomonocytic leukemia (n = 4), myelodysplastic syndrome (n = 4), or a myeloproliferative neoplasm (n = 3). Mutations in TET2 (37%), ASXL1 (26%), RNA splicing factor (19%), NRAS/KRAS/FLT3 (15%), and TP53 (7%) were observed.

    For patients with relapsed/refractory disease, prior therapies included tagraxofusp (64%), pivekimab sunirine (IMGN632; 36%), venetoclax (27%, 2 with a hypomethlyating agent), and SCT (36%).

    Patients with previously untreated BPDCN received a median of 2.5 cycles (range, 1-4) of treatment. In the relapsed/refractory group, the median number of cycles was 2 (range, 1-5).

    What additional safety and efficacy data were reported at the meeting?

    For patients with previously untreated BPDCN, the median OS, PFS, and DOR were all NR. The 2-year PFS and OS rates were 65% (95% CI, 40%-91%) and 53% (95% CI, 30%-80%), respectively. In the relapsed/refractory group, the median OS was 8.4 months (95% CI, 4.8-21.7) and the median PFS was 6.3 months (95% CI, 2.2-11.2). The median DOR was 7.2 months (95% CI, 5.5-36.4).

    In the overall patient population, the most common grade 3 or higher treatment-related AEs were thrombocytopenia (63%), decreased white blood cell count (59%), neutropenia (48%), anemia (19%), and hypoxia (11%). Other AEs included increased ALT levels, increased AST levels, atrial fibrillation, febrile neutropenia, hyperglycemia, hypophosphatemia, multi-organ failure, sinus tachycardia, and syncope (4% each).

    No cases of veno-occlussive disease were reported. In the overall patient population, the all-cause mortality rates at 30- and 60-days were 3.7% and 7.4%, respectively. One patient with first-line BPDCN died in cycle 1 due to multi-organ failure, and 1 patient with relapsed/refractory disease died after cycle 1 due to disease progression. The median time from the start of cycle 1 to cycle 2 was 33 days.

    Disclosures: Lane received consultancy fees from ProteinQure, IDRx, Cimeio, Qiagen, Jnana Therapeutics, Stemline, and AbbVie. He also holds stock options in Stelexis BioSciences and Stemline.

    References

    1. Lane AA, Luskin M, Keating J, et al. Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): results of a phase 2 trial. Blood. 2025;146(suppl 1):653. doi:10.1182/blood-2025-653
    2. Lane AA, Garcia JS, Raulston EG, et al. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood. 2024;8(3):591-602. doi:10.1182/bloodadvances.2023011721

    Continue Reading